TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

20A.66 Le Tiec C et al. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 2005;44:1035-50. 20A.67 Fuster D et al. Review of atazanavir: a novel HIV protease inhibitor. Expert Opin Pharmacother 2005;6:1565-72. 20A.68 Havlir DV et al. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis 2004;38:1599- 604. 20A.69 Becker S. Atazanavir: improving the HIV protease inhibitor class. Expert Rev Anti Infect Ther 2003; 1:403-13. 20A.70 European Medicines Agency (EMA). European assessment report (EPAR). Prezista, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000707/WC500041756.pdf. Accessed on August 20 th 2010. 20A.71 Back D et al. Darunavir: pharmacokinetics and drug interactions. Antiviral Ther 2008;13:1-13. 20A.72 Fenton C et al. Darunavir in the treatment of HIV-1 infection. Drugs 2007;67:2791-801. 20A.73 El-Atrouni WI et al. Darunavir. Drugs Today 2007;43:671-9. 20A.74 McCoy C. Darunavir: A nonpeptidic antiretroviral protease inhibitor. Clin Ther 2007;29:1559-76. 20A.75 Rittweger M et al. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007;46:739-56. 20A.76 Molina JM et al. Darunavir: a nonpeptidic antiretroviral protease inhibitor. Expert Opin Pharmacother 2007;8:1951-64. 20A.77 European Medicines Agency (EMA). European assessment report (EPAR). Telzir, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_li brary/EPAR_- _Product_Information/human/000534/WC500035345.pdf. Accessed on August 20 th 2010. 20A.78 Torres HA et al. Fosamprenavir plus ritonavir for HIV infection. Expert Rev Anti Infect Ther 2007;5: 349-63. 20A.79 Arvieux C et al. Amprenavir or fosamprenavir plus ritonavir in HIV infection. Pharmacology, efficacy and tolerability profile. Drugs 2006;65:633-59. 20A.80 Chapman TM et al. Fosamprenavir. A review of its use in the management of antiretroviral therapynaive patients with HIV infection. Drugs 2004;64:2101-24. 20A.81 Wire MB et al. Fosamprenavir. Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet 2006;45:137-68. 20A.82 Becker S et al. Fosamprenavir. Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Expert Opin Pharmacother 2004;5:1995-2005. 20A.83 Hester EH et al. Fosamprenavir: drug development for adherence. Ann Pharmacother 2006;40: 1301-10. 20A.84 European Medicines Agency (EMA). European assessment report (EPAR). Crixivan, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000128/WC500035730.pdf. Accessed on August 20th 2010. 20A.85 Rayner CR et al. A critical evaluation of the therapeutic range of indinavir. Ann Pharmacother 2002; 36:1230-7. 20A.86 Boyd M. Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role? Expert Opin Pharmacother 2007;8:957-64. 20A.87 Plosker GL et al. Indinavir. A review of its use in the management of HIV infection. Drugs 1999;58: 1165-203. 20A.88 Wu DS et al. Indinavir urolithiasis. Curr Opin Urol 2000;10:557-61. 20A.89 Famularo G et al. Symptomatic crystalluria associated with indinavir. Ann Pharmacother 2000;34: 1414-8. 20A.90 Yeh KC et al. Single dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 1998;42:332-8. 20A.91 Colson AE et al. Paronychia in association with indinavir treatment. Clin Infect Dis 2001;32:140-3. 20A.92 Florence E et al. Rheumatological complications associated with the use of indinavir and other protease inhibitors. Ann Rheum Dis 2002;61:82-4. 20A.93 European Medicines Agency (EMA). European assessment report (EPAR). Kaletra, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000368/WC500039043.pdf. Accessed on August 20 th 2010. 20A.94 Tan D et al. Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections. Expert Rev Anti Infect Ther 2007;5:13-28. 20A.95 Walmsley S et al. The role of lopinavir/ritonavir in the management of HIV infected adults. Expert Rev Anti Infect Ther 2003;1:389-401. 20A.96 Barragan P et al. Lopinavir/ritonavir: a protease inhibitor for HIV-treatment. Expert Opin Pharmacother 2008;9:2363-75. 20A.97 von Hentig N. Lopinavir/ritonavir: appraisal of its use in HIV therapy. Drugs Today 2007;43:221-47. 20A.98 Oldfield V et al. Lopinavir/ritonavir. A review of its use in the management of HIV infection. Drugs 2006;66:1275-99. 20A.99 Kaplan SS et al. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection. J Antimicrob Chemother 2005;56:273-6. 20A.100 Vogel M et al. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection. Expert Opin Drug Saf 2005;4:403-20. 20A.101 Corbett AH et al. Kaletra (lopinavir/ritonavir). Ann Pharmacother 2002:36:1193-203. 20A.102 European Medicines Agency (EMA). European assessment report (EPAR). Viracept, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000164/WC500050679.pdf. Accessed on August 20 th 2010. 20A.103 Perry CM et al. Nelfinavir. A review of its use in the management of HIV infection. Drugs 2005;65: 2209-44. 20A.104 Tebas P et al. Nelfinavir mesylate. Expert Opin Pharmacother 2000;1:1429-40. 20A.105 European Medicines Agency (EMA). European assessment report (EPAR). Norvir, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000127/WC500028728.pdf. Accessed on August 20 th 2010.. 20A.106 Zeldin RK et al. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:4-9. 20A.107 Cooper CL et al. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 2003;36:1585-92. 20A.108 Rathbun RC et al. Low-Dose ritonavir for protease inhibitor pharmacokinetic enhancement. Ann Pharmacother 2002;36:702-6. 20A.109 European Medicines Agency (EMA). European assessment report (EPAR). Invirase, summary of pro-
duct characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000113/WC500035084.pdf. Accessed on August 20 th 2010. 20A.110 Johnson M et al. Saquinavir/low-dose ritonavir: its use in HIV infection. AIDS Rev 2003;5:44-51. 20A.111 Plosker GL et al. Saquinavir. A review of its use in boosted regimens for treating HIV infection. Drugs 2003;63:1299-324. 20A.112 European Medicines Agency (EMA). European assessment report (EPAR). Aptivus, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000631/WC500025936.pdf. Accessed on August 20 th 2010. 20A.113 Courter JD et al. Tipranavir: a new protease inhibitor for the pediatric population. Expert Rev Anti Infect Ther 2008;6:797-803. 20A.114 Temesgen et al. Tipranavir: a new option for the treatment of drug-resistant HIV Infection. Clin Infect Dis 2007;45:761-9. 20A.115 Luna B et al. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther 2007;29:2309-18. 20A.116 King JR et al. Tipranavir. A novel nonpeptidic protease inhibitor of HIV. Clin Pharmacokinet 2006; 45:665-82. 20A.117 Dong BJ et al. Tipranavir: a protease inhibitor for HIV salvage therapy. Ann Pharmacother 2006;40: 1311-21. 20A.118 Temesgen Z et al. Tipranavir. Drugs Today 2005;41:711-20. 20A.119 Croom KF et al. Tipranavir. A ritonavir-boosted protease inhibitor. Drugs 2005;65:1669-77. 20A.120 Kandula VR et al. Tipranavir: a novel second-generation nonpeptidic protease inhibitor. Expert Rev Anti Infect Ther 2005;3:9-21. 20A.121 Mehandru S et al. Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection. Expert Opin Investig Drugs 2003;12:1821-8. 20A.122 Justice AC et al. Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage? Clin Infect Dis 2008;47:1226-30. 20A.123 Yeni P. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J Acquir Immune Defic Syndr 2003;34(suppl. 1):S91-4. 20A.124 European Medicines Agency (EMA). European assessment report (EPAR). Ziagen, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000252/WC500050343.pdf. Accessed on August 20 th 2010. 20A.125 Hervey PS et al. Abacavir. A review of its clinical potential in patients with HIV infection. Drugs 2000; 60:447-79. 20A.126 Yuen GJ et al. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet 2008;47:351-71. 20A.127 Saag M et al. High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008;46:1111-8. 20A.128 Mallal S et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568- 79. 20A.129 Rauch A et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort Study. Clin Infect Dis 2006;43:99-102. 20A.130 Hughes CA et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother 2008;42:387-96. 20A.131 Clay PG et al. Management protocol for abacavir-related hypersensitivity raction. Ann Pharmacother 2000;34:247-9. 20A.132 Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther 2002;24:1502-14. 20A.133 Behrens GM et al. Abacavir and cardiovascular risk. Curr Opin Infect Dis 2010;23:9-14. 20A.134 D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417-26. 20A.135 Moreno S et al. Didanosine enteric-coated capsule current role in patients with HIV-1 infection. Drugs 2007;67:1441-62. 20A.136 European Medicines Agency (EMA). European assessment report (EPAR). Emtriva, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000533/WC500055586.pdf. Accessed on August 20 th 2010. 20A.137 Saag MS. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin Infect Dis 2006;42:126-31. 20A.138 Frampton JE et al. Emtricitabine. A review of its use in the management of HIV infection. Drugs 2005; 65:1427-48. 20A.139 Molina JM et al. Emtricitabine: a novel nucleoside reverse transcriptase inhibitor. Drugs Today 2005; 41:241-52. 20A.140 Modrzejewski KA et al. Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor. Ann Pharmacother 2004;38:1006-14. 20A.141 Cahn P. Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor. Expert Opin Investig Drugs 2004;13:55-68. 20A.142 European Medicines Agency (EMA). European assessment report (EPAR). Epivir, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000107/WC500027572.pdf. Accessed on August 20 th 2010. 20A.143 Bessesen M et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28: 1032-5. 20A.144 Sellier P et al. Fatal interruption of a 3TC-containing regimen in a HIV-infected patient due to re-activation of chronic hepatitis B virus infection. Scand J Infect Dis 2004;36:533-5. 20A.145 European Medicines Agency (EMA). European assessment report (EPAR). Zerit, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Pro duct_Information/human/000110/WC500049165.pdf. Accessed on August 20 th 2010. 20A.146 Cheer SM et al. Stavudine once daily. Drugs 2002;62:2667-74. 20A.147 Joly V et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002;16:2447-54. 20A.148 Boubaker K et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV cohort study. Clin Infect Dis 2001;33:1931-7. 20A.149 Coghlan ME et al. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 2001;33:1914-21. 20A.150 European Medicines Agency (EMA). European assessment report (EPAR). Viread, summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
Page 1 and 2:
TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4:
1.89 Laupland KB. Vascular and para
Page 5 and 6:
of NICE guidance. Br Med J 2008;337
Page 7 and 8:
tions à Clostridium difficile dans
Page 9 and 10:
sis of placebo-controlled trials. C
Page 11 and 12:
1.446 Centers for Disease Control a
Page 13 and 14:
1.532 Olaison L et al. Enterococcal
Page 15 and 16:
1.615 Muder RR et al. Isolation of
Page 17 and 18:
2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20:
2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22:
1.873 Korting HC et al. Current top
Page 23 and 24:
1.970 Thomas RJ et al. Current mana
Page 25 and 26:
of severe respiratory failure. Clin
Page 27 and 28: 1.1166 Aldape MJ et al. Clostridium
Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33 and 34: 2B.39 Cookson BD et al. Guidelines
Page 35 and 36: 2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43 and 44: among hospitalized patients. Clin I
Page 45 and 46: Ther 2006;4:947-52. 5D.1 Demirovic
Page 47 and 48: 7.38 Meersseman W et al. Invasive a
Page 49 and 50: 7.121 Walsh TJ et al. All catheter
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73 and 74: 18.12 Panel on Antiretroviral Thera
Page 75 and 76: 18.91 Lesho E. Evidence base for us
Page 77: tients. J Antimicrob Chemother 2009
Page 81 and 82: _Product_Information/human/000338/W
Page 83 and 84: 114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86: North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88: 1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90: 21.358 Calabrese LH et al. Viral Ar
Page 91 and 92: 24. 21.452 Jeha LE et al. Long term
Page 93 and 94: induced functional androgen deficie
Page 95 and 96: 25A.27 Conseil Supérieur de la San
Page 97 and 98: product characteristics. Available
Page 99 and 100: mortality after kidney transplantat
Page 101 and 102: 33A.1 Kearney BP et al. The penetra
Page 103 and 104: Clin Plast Surg Clinics in Plastic
Page 105 and 106: Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

Create successful ePaper yourself

Delete template?

Save as template?